To include your compound in the COVID-19 Resource Center, submit it here.

Lyxumia lixisenatide: Additional Phase III data

Additional data from the open-label, international Phase III GetGoal-X trial in 634 Type II diabetics inadequately controlled with metformin showed that once-daily Lyxumia as an add-on to

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE